Treatments

*July 2022* Leveraging EGFR TKIs as a backbone for combination therapies will be pivotal for expanding treatment options and delivering more personalized therapies in the first-line setting for patients with non–small cell lung cancer (NSCLC) harboring EGFR mutations, according to Marina Garassino, MD. Single-agent osimertinib (Tagrisso) remains the standard of care for…

*July 2022* Although it is known that anti-PD1/L1 monotherapy does not render significant benefit in patients with EGFR-mutant lung adenocarcinoma, whether the addition of anti-PD1/L1 therapy to chemotherapy can enhance chemotherapy efficacy for TKI-refractory EGFR-mutant lung adenocarcinoma patients is not clear. To address this question, we retrospectively analyzed a cohort…

*July 2022* Introduction BRAF variants were reported resistant mechanisms to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant NSCLC. Nevertheless, characteristics and subsequent treatment strategies of such patients remain unclear. Methods From October 2016 to May 2020, patients with advanced NSCLC for whom next-generation sequencing detected mutations of both BRAF and…

*July 2022* — A roundtable of experts predict what the future holds for treatment of the disease  New clinical research unveiled at the recent American Society of Clinical Oncology (ASCO) annual meeting has the potential to significantly alter the treatment of lung cancer. But what will be the innovations we…

*July 2022* Panelists review clinical trial data in the setting of EGFR-mutant advanced NSCLC and consider which therapy they would use at progression. Benjamin P. Levy, MD, Chaitali Nangia, MD, Patty and George Hoag Cancer Center, Jessica Donington, MD, MSCR, Jonathan Riess, MD, Alexander Spira, MD, PhD, FACP, Heather Wakelee,…

*June 2022* During this event, information about EGFR-mutant lung cancer, research advances, symptom management, as well as hearing from patients and caregivers were discussed.  Watch the webcast here.

*June 2022* John Heymach, MD, PhD, discusses the poor outcomes that have been observed with immunotherapy in patients with NSCLC and EGFR mutations or ALK rearrangements. An important exception to the use of PD-L1inhibitors as first-line therapy is for patients with oncogenic drivers. This is most strongly the case with…

*June 2022* In these podcasts, Narjust Duma, MD, an assistant professor of medicine at Harvard Medical School, and physician and associate director of the Cancer Equity Program at Dana-Farber Cancer Institute, discusses lung cancer in women. Lung cancer is far and away the leading cause of cancer deaths in American…

*June 2022* Presented by CEC ONCOLOGY with Dr. Helena Yu, Dr. Natasha B. Leighl, and EGFR Resisters Cofounder Jill Feldman This Rapid Recap provides a responsive, timely, and incisive overview of data presented at the 2022 Clinical Oncology Annual Meeting (ASCO), and offers expert insights into the shifting management landscape for…